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ABSTRACT
Objectives: There is no standardized treatment modality or a generally accepted guideline in cesarean scar pregnancy 
(CSP) treatment. The aim of this study is to retrospectively evaluate the outcomes of the different treatment modalities 
used in CSP treatment. 
Material and methods: 31 CSP patients retrospectively evaluated between May 2011 and February at Uludag University 
Hospital in Bursa, Turkey included in the study. A graphical flowchart according to the treatment modalities and timeline 
graphics of the patients were used. Main outcome measures were recurrent CSPs and healthy pregnancies in clinical 
follow-up after a successful CSP treatment. 
Results: 31 CSP patients were treated with six different treatment modalities in our series. Recurrent CSP was diagnosed 
in three patients after a successful CSP treatment. All of these recurrent CSPs were treated with D/C procedure in their first 
CSP. Six patients conceived again in clinical follow-up after successful treatment of CSP. 
Conclusions: CSP is a serious maternal complication that risks the mother’s life, and this problem is growing because of 
the increased cesarean rates. Invasive procedures applied to the uterus in CSP treatment may cause recurrent CSP in the 
next pregnancy of the patient. When considering the treatment options of the CSP, minimally invasive treatment modalities 
and the subsequent gestation of the patient should be taken into account.
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INTRODUCTION
Cesarean rates have shown a significant increase in the 
last two decades although all the medical precautions are 
taken all over the World [1]. Parallel to this increase, cesar-
ean rates in Turkey unprecedentedly escalated from 21 per-
cent in 2002 to 53 percent in 2015 [2] . Although these rates 
are higher in Turkey, cesarean rates were 28 percent in the 
upper-income group, 32 percent in the upper-middle-in-
come group and 17 percent in all over the world according 
to the WHO health statistics between 2007 and 2014 [3]. 
As the primary cesarean rates increase, the complications 
in the subsequent pregnancies also increase. Among these 
complications, cesarean scar pregnancies (CSP) and placen-
tal invasion anomalies are the most important ones because 
of the catastrophic pregnancy outcomes [4, 5]. 
Cesarean scar pregnancy was first described in 1978 [6]. 
Although it has been mentioned with many different names, 
CSP has become the most common definition in recent years 
[7, 8]. There was a significant increase in CSPs due to the rise 
in the rates of cesarean section [9]. The probability of CSP 
in a pregnant patient who had a previous cesarean section 
is approximately 1 in 2000 pregnancies [10]. Although it is 
mentioned in the literature that the diagnosis of CSP is prob-
lematic, it can be diagnosed if attention is paid to implanta-
tion localization [11]. The difficult part is to make a treatment 
plan on a subject where the treatment is not standardized, 
and there are no generally accepted guidelines worldwide. 
Patients who demand the continuation of their pregnancy, 
there is a dangerous process that goes from morbidly adher-
ent placenta (MAP) to maternal mortality [12].
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In this study, a retrospective analysis of thirty-one cesar-
ean scar pregnancies which we treated in the last six years, 
has been done in our university hospital. The outcomes of 
different CSP treatment modalities and normal pregnan-
cies or recurrent after the treatments in clinical follow-up 
were analyzed.  
MATERIALS AND METHODS
This article includes retrospective data from 31 CSP 
patients who were examined in Uludag University Hospital 
Bursa, Turkey between May 2011 and February 2017. Weekly 
or monthly monitored β-HCG (human chorionic gonado-
tropin) levels in patient records were analyzed, and time-
line graphics of each patient were prepared. Transvaginal 
ultrasonographic evaluations (Philips ClearVue 650, Philips 
Healthcare, The Netherlands) during diagnosis, treatment, 
and follow-up were taken from the patient files. The pres-
ence or absence of fetal heart activity (FHA) was also ex-
tracted from the patient records. 
Since there is no standard definition for CSP diagnosis, 
the presence of all clinical findings which were described 
below is used to diagnose CSP [4]. 
1. An empty uterine cavity and a closed and empty cervi-
cal canal.
2. The placenta ± a gestational sac embedded in the hys-
terotomy scar
3. A rich vascular pattern in the area of the cesarean scar 
with a positive pregnancy test
4. Absent myometrial layer between the gestational sac 
and the bladder
5. A triangular or rounded gestational sac that fills the 
niche of the scar
6. The presence of embryonic pole ± yolk sac with or with-
out heart activity.
Treatment options are offered to each patient after 
the CSP was diagnosed. Details of the advantages and 
complications of each treatment are provided. Their clini-
cian decided assignment of the women to one of the six 
treatment methods. The treatment decision is reported 
to the patient, and the patient’s informed written con-
sent is obtained. Patients are monitored with the pelvic 
examination, B-HCG test, and ultrasonography in our 
outpatient clinic once in a week or month regularly for up 
to 2 years after the treatment. Women were reevaluated 
by ultrasonography for isthmocele before their subse-
quent pregnancy.
There were six primary treatment modalities which were 
used in cesarean scar pregnancies in our clinic. These were; 
Observational approach, Dilatation, and Curettage (D/C) 
procedure, D/C plus Systemic Methotrexate (MTX) Therapy, 
Systemic MTX therapy, Local MTX Therapy, and Combined 
Methotrexate Therapy. 50 mg/m2 MTX via intramuscular 
administration was used for systemic MTX therapy. An oo-
cyte retrieval needle with 25 mg MTX was used for the local 
MTX therapy. Details of the procedures are defined in the 
Supplementary Material 1.
Statistical Analysis and Ethical Implications
Basic demographic indicators and descriptive statistics 
were calculated with SPSS Statistics 23, (IBM Corporation, 
NY, USA) and Excel spreadsheet (Microsoft Windows Excel 
2016, Redmond, WA, USA)]. Measurements are presented as 
individual values and means. Institutional ethics committee 
approval was obtained for the analysis of this retrospective 
data (2017-18/24).
RESULTS
Thirty-one CSP patients detected in our hospital records 
within six years. Demographic characteristics of the patients 
and the main aspects of the treatments are shown in Table 1. 
Six treatment modalities used in our clinic are explained in 
detail in Figure 1. 
FHA:(+) CSP patients
Fetal heart activity was positive in 18 patients (58.06%). 
Patient-13 was evaluated with the observational approach 
because of her request for the continuation of her preg-
nancy by undertaking all the risks. 
We performed a D/C procedure to five patients (Pa-
tient 3, 10, 17, 21 and 26). Patient 3, 10, 21 and 26 were 
treated after D/C procedure. Patient 17 received an addi-
tional treatment of revision curettage on the second day 
after D/C with a rest placental fragment and abundant 
vaginal bleeding indication. CSP recurred in Patient 3 and 
10 in their subsequent pregnancy despite the successful 
D/C treatment. In total, three of the five patients who 
underwent the D/C procedure were treated (60%), but 
two were recurrent cesarean scar pregnancies again in 
their next pregnancy (40%). 
Five patients (Patient 12, 23, 25, 30 and 31) were treated 
with D/C plus systemic MTX therapy, and all of them were 
treated. 
There were no patients treated with local MTX therapy 
in FHA:(+) CSP patients. 
Patient 4 and Patient 24 received systemic MTX therapy. 
Patient 4 was treated while Patient 24 had an additional 
treatment due to the B-HCG levels which were drawing 
plateau. She received second systemic MTX therapy after 
one week later from the first systemic MTX treatment and 
was treated in 31 days. 
Combined MTX treatment was used in 5 patients (Pa-
tient 2, 6, 9, 20 and 22). All of them were treated. Patient 
6 and 9 conceived after combined MTX treatment of cesar-
ean scar pregnancies. 
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FHA:(-) CSP patients
There was only one patient (Patient 5) who were treated 
with the observational approach. 
Five patients (Patient 7, 16, 18, 19 and 29) underwent 
a D/C procedure, and all of them were treated. Patient 7 was 
diagnosed with recurrent CSP after 100 days from the D/C 
procedure. Systemic MTX and D/C procedure were admin-
istrated, and she was treated in 21 days. 
Only Patient 1 was treated with D/C procedure plus 
systemic MTX therapy together in FHA:(-) CSP patients. 
There were two patients (Patient 14 and 28) who re-
ceived local MTX therapy in FHA:(-) CSP patients. 
Systemic MTX therapy was administered to Patient 8, 
11 and 27 (Fig. 2). However, an urgent revision curettage was 
required in Patient 11 after 55 days from the CSP treatment 
due to the excessive vaginal bleeding. Patient 27 conceived 
623 days after the CSP treatment. 
Combined MTX therapy was performed to Patient 
15. However, an additional revision curettage had to be 
performed 28 days after the CSP treatment due to the abun-
dant vaginal bleeding. She was treated in 47 days. 74 days 
later this woman underwent a laparoscopic cesarean scar 
defect (isthmocele) excision with an indication of postmen-
strual spotting and pelvic pain. Detailed timeline graphics 
of all the CSP patients are shown in detail in Supplementary 
Material 2.
Patients conceived in clinical follow-up after the 
CSP treatment
Nine women conceived in clinical follow-up after B-HCG 
levels were negative in their first CSP treatments (Fig. 2). 
Three women (Patient 3, 7 and 10) were diagnosed as CSP 
again. The remaining six patients (Patient 4, 5, 6, 9, 24 and 
27) were conceived spontaneously on clinical follow-up 
(Fig. 3). Five patients had regular pregnancy follow-up and 
underwent cesarean section at 33rd gestational weeks in 
patient 4, 35th weeks in patient 6, 34th weeks in patient 
9, 35th weeks in patient 24 and 34th weeks in patient 
27 respectively. Patient 5 was still pregnant at the time 
of writing this article. Perinatal and neonatal outcomes of 
the patients who conceived after the CSP treatments are 
shown in Table 2. Abnormal placental invasion or morbidly 
adherent placenta was not found in pregnancies of these 
patients. However, an incomplete rupture observed at the 
previous cesarean scar site during cesarean section in 3 pa-
tients (Patient 6, 9 and 27).    
Recurrent CSP patients
After successful treatment of the CSPs, three patients 
(Patient 3, 7 and 10) were detected as recurrent CSP in their 
next pregnancy (Fig. 2). Patient 7 and Patient-10 treated with 
D/C (As their gestational sac were adjacent to the cervical 
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Table 2. Perinatal and pregnancy outcomes of caesarean scar pregnancy patients who were successfully treated and became pregnant again 
in clinical follow-up.
Gestational 
week
Delivery 
route
AGGAR scores
Newborn 
weight (gr)
Gender Notes
Patient-4
332 weeks twin 
pregnancy
C/S
8 9
1905 1845 Female Female Twin pregnancy. No complication until birth.
7 8
Patient-5
Pregnant at 
the moment
- - - - -
She is now in the 21st gestational week and have 
not any complication of pregnancy.
Patient-6
351 weeks 
pregnancy
C/S 9 9 2864 Female
Bilateral tubal ligation was performed at the 
time of cesarean section. Incoplete rupture was 
detected at the time of cesarean section.
Patient-9
342 weeks 
pregnancy
C/S 9 10 2658 Female
Oligohydramnios was observed at 30th 
gestational week and she delivered via C/S. 
Incomplete rupture were detected at the time of 
cesarean section.
Patient-24
354 weeks 
pregnancy
C/S 8 9 2973 Female
Preterm labor was complicated the pregnancy 
and C/S was performed.
Patient-27
342 weeks 
pregnancy
C/S 9 9 3238 Male
Incomplete rupture was detected at the time of 
cesarean section. Postpartum depression was 
diagnosed. She was consulted with psychiatry 
clinic.
canal) plus systemic MTX therapy and Patient 3 with com-
bined MTX therapy. Detailed timeline graphics of recurrent 
CSP cases are shown in Figure 4.
DISCUSSION
With the increase of the cesarean rates, two main clinical 
conditions which are early placenta accreta and CSP have 
threatened the subsequent pregnancy of the women in 
recent years. Both of these complications may risk women’s 
life [13]. While placental invasion abnormalities have long 
been a primary concern of obstetrics, the definition of CSP 
is a new clinical entity. As cesarean rates increase, more 
patients are diagnosed with CSP every year [5]. 
There are two fundamental problems in managing 
CSPs. The first problem is the diagnose, which is really difficult 
for CSPs especially for clinicians working in the primary care 
centers [14]. The second and the main problem is the treatment. 
Experiences about diagnosis are increasing day by day. How-
ever, the same situation cannot be applied to the treatment 
since there are no established guidelines in CSP treatment. 
In a study, combined local and systemic MTX treatment was 
found to be effective in 19 out of 26 cases [13]. In our data, five 
FHA:(+) CSP patients treated with combined treatment and all 
of them were treated. Two patients were pregnant afterward 
and delivered healthy babies via cesarean section. 
The observational approach in CSP may have problem-
atic consequences. In an article with 60 cases, high-rate 
hysterectomy had to be performed in cases which an ob-
servational approach was applied [15]. In our study, two 
patients requested the continuation of CSP pregnancy. 
We had to perform a hysterectomy to Patient 13. Patient 
5 who had an FHA:(-) CSP, was spontaneously aborted in 
clinical follow-up. Similarly, in a recently published review, it 
was stated that CSPs with negative fetal heart activity might 
terminate spontaneously in expectant management [16].
What is the most significant complication if the patient 
is diagnosed with CSP and wants to continue her preg-
nancy? The answer is inevitably morbidly adherent placenta. 
If an observational approach is applied, almost all of these 
women develop MAP. In a trial, ten CSP cases evaluated 
with the observational approach and MAP observed in all 
of them [9]. However, all of these patients undergoing the 
observational approach were FHA:(+) CSP patients. The 
observational approach was noted only in two women in 
our study. A placenta accreta with early diagnosis and a CSP 
case cannot be distinguished from each other histopatho-
logically [17]. Both of these clinical entities will inevitably 
advance to MAP. Therefore, if an FHA:(+), CSP woman is to 
be followed up with an observational approach then she 
should be informed in detail about the catastrophic conse-
quences of the treatment including hysterectomy. 
The D/C procedure has always been up to date since the 
CSP definition was first introduced in the late seventies [4]. 
It is safer and cost-effective when done in guidance with USG 
[18, 19]. However, the most fundamental problem of this 
procedure is the distance between CSP sac and the cervical 
canal. Because the longer the range of CSP-cervical canal 
is, the harder it is to reach CSP with the curette. Therefore, 
the use of the D/C procedure alone in the treatment of CSP 
significantly reduces success rates [20]. In a recent review, 
it has stated that the D/C procedure could be successful 
only with the addition of other treatments such as uterine 
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Figure 4. Recurrent CSP patients. There were 3 recurrent CSP cases (Patient-3, 7 and 10) detected from the patient files in clinical follow-up of 
the treated CSP patients. All of these three patients were treated with D/C procedure in their first caesarean scar pregnancies. After diagnosis of 
recurrent CSP, patient-3 were treated with combined MTX therapy. While patient 7 and 10 were treated with D/C plus systemic MTX therapy
Figure-4: Recurrent CSP patients 
There were 3 recurrent CSP cases (Patient-3, 7 and 10) detected from the patient files in clinical follow-up of the  
treated CSP patients. All of these three patients were treated with D/C procedure in their first caesarean scar  
pregnancies. After diagnosis of recurrent CSP, patient-3 were treated with combined MTX therapy. While patient 7  
and 10 were treated with D/C plus systemic MTX therapy.  
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Figure-4: Recurrent CSP patients 
There were 3 recurrent CSP cases (Patient-3, 7 and 10) detected from the patient files in clinical follow-up of the  
treated CSP patients. All of these three patients were treated with D/C procedure in their first caesarean scar  
pregnancies. After diagnosis of recurrent CSP, patient-3 were treated with combined MTX therapy. While patient 7  
and 10 were treated with D/C plus systemic MTX therapy.  
artery embolization or MTX therapy [21]. We have observed 
that the most significant handicap of the D/C procedure is 
recurrent CSP. Three recurrent CSP cases in our series were 
treated by only D/C procedure in their first CSP. However, CSP 
patients who treated with D/C plus systemic MTX therapy 
were all treated, and none of them recurred. It can be hy-
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pothesized that while D/C procedure alone is inadequate in 
the treatment of CSP, D/C plus systemic MTX therapy may 
be useful. Since the recurrent CSP is ubiquitous after the 
D/C procedure, a recent trial has shown that the operative 
hysteroscopy is useful in such cases [22]. 
Non-surgical treatments might also be of interest in the 
treatment of CSP. Uterine artery embolization may be useful 
in CSPs presenting with acute bleeding [23]. The most popular 
non-surgical treatment modality is a chemotherapeutic agent 
administration of a local injection into the CSP sac [24]. Two 
women who had FHA:(-) CSP, received local MTX treatment 
in our cohort. Complete cure was achieved in Patient 14 but 
Patient 28 has still complaints about vaginal spotting, and she 
is in the clinical evaluation process at the moment. Clinicians 
usually want to try the local treatment in locally accessible 
patients or in cases where CSP does not spread volumetrically. 
We think that some main anatomical measurements such 
as the volume of CSP, the distances between CSP-bladder, 
CSP-cervical canal, CSP-fundus uteri, and CSP-external cervi-
cal os should be evaluated to predict which CSP patient will 
be sufficient for the local treatment. Another point is that it is 
unknown why systemic MTX therapy has not been used with 
local MTX therapy and also it is unknown which treatment (lo-
cal, systemic or combined) should be given to which patient. 
Which CSPs can be advanced to the term is controversial. 
In a recent review, the concept of endogenous and exogenous 
growth has been put forward [25]. A CSP which has a potential 
for endogenous growth, can migrate towards the fundus and 
then reach the term. However, the CSP which has a potential 
for exogenous growth is expanding directly into the bladder 
and can lead to catastrophic outcomes. Although we did not 
perform any in our series, laparoscopic management of CSP 
in a previous cesarean section scar with exogenous growth 
can also be considered as an effective treatment method [26].
Noninvasive treatments can be a factor in conceiving 
again in CSPs. Conducting pharmacological therapies rather 
than a destructive treatment as in D/C procedure may facilitate 
normal pregnancy in the clinical follow-up of the treated CSP 
patients. The absence of placental invasion anomalies in six 
pregnancies may be seen as a limitation of this study because 
at least one placental invasion anomaly would have to be ob-
served according to similar retrospective studies [10]. 
In conclusion, the treatment stages of CSP, which clini-
cians have encountered more and more in recent years, 
have not been standardized yet. Successful treatment of 
CSPs with different treatment modalities may be possible. 
The trials in this area consist of numerous retrospective 
analyzes as it is in our study and more randomized trials 
are needed to be done. 
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Supplemental Figure-D: Local MTX therapy administrated CSP patients. Scanning the patient records, there were no FHA:(+) CSP patients who 
were treated by local methotrexate therapy. Patient 14 and 28 were FHA:(-) CSP patients who were treated with local MTX. No pregnancy occured 
after the treatments in clinical follow-up. Patient 28 wants to conceive for the moment but she is being re-evaluated for the vaginal spotting
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